%20BIANCO.png)
Pipeline
Our compounds target components of the solid tumor microenvironment to foster anti-cancer immune response enhancing the recruitment, activation and sustained function of cytotoxic T lymphocytes against solid tumors.
LVB 001
SEMA3A
Mutant SEMA3A
is a PlexinA4-selective superagonist for cancer treatment that normalizes tumor vasculature and induces tumor-restraining CAF polarization.
PlexinA4
is a semaphorin receptor that negatively controls cytotoxic T lymphocytes migration in cancer.
LVB 002
PlexinA4
SLC4A4
LVB 003
SCL4A4
is a bicarbonate transporter that induces bicarbonate uptake by cancer cells and increases TME acidity.
Undisclosed
LVB-004
Undisclosed
LVB-005
Undisclosed
Undisclosed
Linoleic acid (LA)
is a major positive regulator of cytotoxic T lymphocyte activity by improving metabolic fitness, preventing exhaustion and stimulating a memory-like phenotype with superior effector functions.
LVB-006
LA
Our approach aims at reprogramming the solid tumor microenvironment to unlock the full potential of cancer immunotherapy.
Join Lever Bio in advancing promising research and driving innovative drug development in the immuno-oncology field
